The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The researchers added that early indications from their translational substudies suggest that PET radiomics and immune gene analyses provide promise as biomarkers for response in immunotherapy combinations.
In this video interview from SOHO Asia 2026, Dr. Feng-Ming Tien discusses the critical link between the immune microenvironment and therapeutic success in MDS and AML.
Don’t miss the SOHO 2026 poster walks taking place from Wednesday to Friday during the SOHO 2026 Annual Meeting. More information at soho.click/2026.
The clearance allows the expansion of an international, phase 3 trial (CT103AC004) into Japan. This multi-center study evaluates the efficacy and safety of the therapy against standard treatment in patients who are refractory to lenalidomide.
The retrospective, single-center cohort study used linked data from the Princess Margaret Cancer Centre lymphoma database.
To access the SOHO Career Center click the following link.
